FEATURES OF BONE METABOLISM (SCLEROSTIN, KATESININE K) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND POSTMENOPAUSAL OSTEOPOROSIS.

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Backgraund:deterioration of bone quality in type 2diabetes mellitus leads to a decreased strength and an increased risk of low-energy fractures.

Aims:to study the features of bone metabolism in patients with type 2 diabetes mellitus and postmenopausal osteoporosis.

Materials and methods:102 women in the postmenopausal period at the age of 46 to 67 years were examined. All patients were divided into 4 groups: 39 patients with type 2 diabetes (T2DM) and postmenopausal osteoporosis (PO) in the first group, 25 patients with PO in the second group, 21 patients in the third group with T2DM, in the fourth group (control) - 17 people. The study of ionized calcium, phosphorus, total alkaline phosphatase (ALP), parathyroid hormone, 25 (OH) vitamin D, bone mineral density was performed in the first three groups, sclerostin and cathepsin K was performed in the first, second and control groups.

Results: there was no significant difference in sclerostin levels between groups, apositive association was found between sclerostin and НВА1с (r = 0.43, p = 0.009) in the group of patients with T2DM and PO, a negative association was found between sclerostin and ionized calcium (r = -0.45, p = 0.037)in the group of patients with PO. The level of cathepsin K in the group of T2DM and PO was significantly lower than in the level in the PO group (p = 0.046). In the groups with diabetes there was a lower level of 25 (OH) vitamin D. The ALP in the group of T2DM was significantly lower than in the PO group (p = 0.022). The total alkaline phosphatase in the groups with CD2 was significantly lower than in the PO group, and negatively correlated with the duration of the menopause..

Conclusions: lower bone metabolism in type 2 diabetes mellitus  is one of the pathogenetic mechanisms of bone strength reduction.

About the authors

Guzel Nurullina

ФГБОУ ВО "Ижевская государственная медицинская академия" Министерства здравоохранения Российской Федерации
БУЗ УР "1 РКБ МЗ УР"

Author for correspondence.
Email: dalllila@mail.ru
ORCID iD: 0000-0002-4394-8446
SPIN-code: 5885-7116

аспирант кафедры факультетской терапии с курсами эндокринологии и гематологии

врач-эндокринолог

Russian Federation, 426034, Россия, г. Ижевск, ул. Коммунаров, 281 426039, Россия, г. Ижевск, улица Воткинское шоссе, д.57  

Guzyal Akhmadullina

ФГБОУ ВО "Ижевская государственная медицинская академия" Министерства здравоохранения Российской Федерации
БУЗ УР "1 РКБ МЗ УР"

Email: guzal-work@mail.ru
ORCID iD: 0000-0003-1876-2516
SPIN-code: 4171-1245

кандидат медицинских наук, доцент кафедры факультетской терапии с курсами эндокринологии и гематологии

врач-эндокринолог

Russian Federation, 426034, Россия, г. Ижевск, ул. Коммунаров, 281 426039, Россия, г. Ижевск, улица Воткинское шоссе, д.57

References

  1. Ogurtsova K, da Rocha Fernandes JD, Huang Yet al.IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res ClinPract. 2017;128:40-50. doi: 10.1016/j.diabres.2017.03.024.
  2. Janghorbani M, Van Dam RM, Willett WC et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505 doi: 10.1093/aje/kwm106
  3. Ferrari S. Diabetes and Bone. Calcif Tissue Int. 2017;100(2):107-108. doi: 10.1007/s00223-017-0234-y.
  4. Hygum K, Starup-Linde J, Harslof T et al. Mechanisms in endocrinology: Diabetes mellitus, a state of low bone turnover – a systematic review and meta-analysis. Eur J Endocrinol. 2017;176(3):R137-R157. doi: 10.1530/EJE-16-0652
  5. РуяткинаЛ.А., ЛомоваА.В., РуяткинД.С. идр. Параметры костного метаболизма у женщин с сахарным диабетом 2 типа в пре- и постменопаузе в обосновании дифференцированного выбора антиостеопоротической терапии. //Остеопороз и остеопатии.–2013. – Т. 16. - №3 – С. 7-10. Ruyatkina L.A., Lomova A.V., Ruyatkin D.S. etal. Parameters of bone metabolism in pre- and postmenopausal women with type 2 diabetes mellitus in therational for the choice of anti-osteoporotic therapy.Osteoporosis and bone diseases. 2013;16(3): 7-10.(in Russ.)]
  6. ZaidiM, TroenB, MoongaBSetal. Cathepsin K, osteoclastic resorption, and osteoporosis therapy. J Bone Miner Res. 2001;16(10):1747-9. doi: 10.1359/jbmr.2001.16.10.1747
  7. Xu F, Ye YP, Dong YH etal. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J HuazhongUnivSciTechnolog Med Sci.2013 ;33(2):244-9. doi: 10.1007/s11596-013-1105-z.
  8. Orimo H. The mechanism of mineralisation and the role of alkaline phosphatase in health and disease.J Nippon Med Sch.2010; 77(1): 4-12
  9. Hay E, Bouaziz W, Funck-Brentano T et al.Sclerostin and Bone Aging: A Mini-Review.Gerontology. 2016;62(6):618-623.doi: 10.1159/000446278
  10. Ardawi MS, Al-Kadi HA, Rouzi AA et al. Determinants of serum sclerostin in healthy pre- and postmenopausal women.J Bone Miner Res. 2011;26(12):2812-22. doi: 10.1002/jbmr.479.
  11. Ardawi MS, Akhbar DH, Alshaikh A et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013;56(2):355-62. doi: 10.1016/j.bone.2013.06.029.
  12. Wu Y, Xu SY, Liu SY et al. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt-signaling. Eur Rev Med Pharmacol Sci. 2017;21(3):470-478.
  13. Raška I Jr, Rašková M1, Zikán V et al. Prevalence and Risk Factors of Osteoporosis in Postmenopausal Women with Type 2 Diabetes Mellitus. Cent Eur J Public Health. 2017;25(1):3-10. doi: 10.21101/cejph.a4717.
  14. García-Martín A, Rozas-Moreno P, Reyes-García R et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012 Jan;97(1):234-41. doi: 10.1210/jc.2011-2186.
  15. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(10):4030-7. doi: 10.1210/jc.2013-2143

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Nurullina G., Akhmadullina G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies